ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,398,121, issued on Aug. 26, was assigned to NUVATION BIO INC. (New York).
"Anti-cancer nuclear hormone receptor-targeting compounds" was invented by David Hung (New York), Son Minh Pham (San Francisco), Sarvajit Chakravarty (Edmond, Okla.), Jiyun Chen (San Francisco), Jayakanth Kankanala (Saint Paul, Minn.), Anup Barde (Noida, India) and Anjan Kumar Nayak (Noida, India).
According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation."
The patent was filed on Nov. 22, 2022, under Application No....